




# MDH-013 for the Treatment of Intractable Solid Cancers

MDH-013 (*Lactobacillus paracasei* EV) is a new class of first-in-class oral & systemic therapeutic indicated for intractable solid cancers, such as colorectal, lung, gastric, pancreatic cancers, and more

## MDH-013

- Naïve (natural) EVs from a single **Lactobacillus** strain



## Value Propositions

1. **First-in-class**: a new modality drug with a novel mechanism of action (MoA)
2. **Very safe**: a newly discovered and safe commensal bacterium *Lactobacillus*-derived EVs
3. **Effective**: a cancer protective and remission-inducing therapy against intractable solid cancers
4. **Convenient administration**: orally- as well as systemically-delivered
5. **Affordable**: cost effective production

# MDH-013: Key Indications & Development Timeline

## Key Indications

- 1) **Colorectal cancer (CRC)**
- 2) **Gastric cancer (GC)**
- 3) **Non small cell lung cancer (NSCLC)**
- 4) **Hepatocellular cancer (HCC)**
- 5) **Pancreatic cancer (PC)**

## Core patent

- ✓ PCT application date at 13/Aug/2019
- ✓ Registered at KR, US (as of July/2022)
- ✓ Pending at > 10 countries (as of July 2022)
- ✓ Asian market: L/O to HKH

## Development Timeline (US)

IND filing ('22)



P1 ('24)



P2 ('26)



Exit